Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × Cardiotoxicity × Clear all

Phase

Phase NA 45 Phase 2 17 Phase 3 10 Phase 4 6 Phase 1/2 4 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 67 Neoplasms 63 Carcinoma, Hepatocellular 45 Prostatic Neoplasms 41 Colorectal Neoplasms 41 Leukemia, Myeloid, Acute 36 Carcinoma, Non-Small-Cell Lung 33 Stomach Neoplasms 30 Precursor Cell Lymphoblastic Leukemia-Lymphoma 29 Neoplasm Metastasis 25 Pancreatic Neoplasms 21 Rectal Neoplasms 20 Multiple Myeloma 20 Lung Neoplasms 19 Recurrence 17 Hematologic Neoplasms 17 Lymphoma 16 Leukemia 15 Colonic Neoplasms 15 Polycystic Ovary Syndrome 14 Esophageal Neoplasms 13 Head and Neck Neoplasms 12 Motor Activity 11 Fatigue 11 Myelodysplastic Syndromes 10 Liver Neoplasms 10 Glioblastoma 9 Esophageal Squamous Cell Carcinoma 9 Depression 9 Brain Neoplasms 9

Interventions

Trimetazidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡